VOLUNTARY ANNOUNCEMENT

POTENTIAL USE OF “AMBROXOL” AS TREATMENT FOR THE NEW CORONAVIRUS INFECTIONS

China NT Pharma Group Company Limited (the “Company”) noticed that according to a news article dated 28 January 2020 reported by 《澎湃新闻》(The Paper), a PRC online news platform, “‘Ambroxol’, which is widely known as Mucosolvan, is an airway lubricant and expectorant commonly used clinically for diseases such as acute and chronic bronchitis. At present, through artificial intelligence drug target screening, Chinese scientists have found that “Ambroxol” has the potential to be used as a treatment for the new coronavirus (2019-nCoV) infections”. In addition, according to the above news article, “in an interview with 《中國科學報》(China Science Daily), 春明(Chu Ming), an associate professor at the School of Basic Medical Sciences of Peking University, said that after comprehensive consideration, the low toxicity of Mucosolvan and the fact that it is a commonly used medicine in the respiratory field would make it be considered as one of the first medicines to be used for observation in clinical trials”.

Suzhou First Pharmaceutical Co., Ltd., a subsidiary of the Company, possesses a medicine called Zhuo’Ao, an “Ambroxol”- (Mucosolvan) medicine. The Company will closely monitor the development in the treatments for the new coronavirus (2019-nCoV) (the “New Coronavirus”) infections. Upon the confirmation of “Ambroxol”- (Mucosolvan) as an effective treatment for the New Coronavirus infections, the Company’s production department will fully cooperate with the PRC government in the mass production of Zhuo’Ao, an “Ambroxol”- (Mucosolvan) medicine, so as to satisfy the market demand and fight against the epidemic with the country and the people together.
The Company will issue further announcement(s) in due course for any further developments in the above matter.

Having made such enquiry with respect to the Company as is reasonable in the circumstances, the board of directors of the Company confirms that it is not aware of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited or Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 29 January 2020

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Tze Shan Hailson Yu, Dr. Hong Yan and Dr. Zhao Yubiao.